Skip to main content

What Tempus AI's Quarter ended Sep 30, 2026 10-Q says: 5 signals

Tempus AI filed its latest 10-Q with the SEC on Nov 2, 2026. It discusses acquisition announced, acquisition completed and AI investment.

Public (TEM)Biotechnology Research5,001 to 10,000 employeestempus.comLinkedIn

Get Tempus AI's live signals in Claude or ChatGPT, or by API

AskWhat changed at Tempus AI this week? Use Autobound signals for tempus.com.
Filed
Nov 2, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
13

Source: Autobound Signal API · 97 signals tracked for Tempus AI · updated

10-Q · latest 10

What Tempus AI's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 5 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 4 signals

    SEC EDGAR
  3. 10-Q · Quarter ended Mar 31, 2026

    Filed · 4 signals

    SEC EDGAR

Showing 10 of 13 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Tempus AI earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Entering $193M five-year data licensing deals with BMS and PathosTempus entered multi-year strategic collaborations to license oncology data and models to Bristol Myers Squibb for up to $138 million, while partnering with BMS and Pathos to build Alzheimer's data sets for $55 million. Over the five-year term, these agreements are expected to generate $193 million in data and applications revenue. This expansion signals significant pharma data pipeline...
Revenue grew 23% to $412M with $25.6M adjusted EBITDAThird-quarter revenue reached $412 million, representing 23% year-over-year growth, driven by a 32% unit volume increase in Oncology and 33% revenue growth in Data and Applications. The company achieved positive adjusted EBITDA of $25.6 million, reaching a cash and marketable securities balance of $854 million.
Pivoting clinical trial matching business to enterprise biopharma modelTempus restructured its TIME real-time clinical trial matching business from a biotech marketplace model to an enterprise-focused offering targeted at its largest biopharma partners. The network connects over a thousand oncologists across the U.S. and currently operates with a client waitlist. Meanwhile, management is intentionally deemphasizing traditional contract research organization (CRO)...
Diagnostics revenue rose 20% to $304M, Oncology up 28%Diagnostics revenue reached $304 million (+20% YoY), driven by Oncology revenues of $173 million (+28% YoY) on 32% volume growth. Hereditary cancer testing contributed $111 million, with volume growth recovering to low double digits in September and October.
Competing with Natera in MRD and Foundation Medicine in solid tumorTempus highlighted its competitive positioning across oncology diagnostic segments, asserting it ranks number 1 or number 2 in solid tumor, liquid biopsy, and hereditary profiling. Management compared its current market push in minimal residual disease (MRD) against Natera to its historical battle against Foundation Medicine in solid tumor profiling. Guardant Health was also cited as a primary...
Absorbing cash burn and gross margin losses from Personalis acquisitionPersonalis currently generates negative gross profit on individual MRD test runs, which Tempus will need to absorb following the transaction's close. Management plans to allocate roughly two-thirds of incremental gross profit dollars to reinvestment, specifically to absorb Personalis' operating burn until reimbursement approvals allow the tests to achieve positive unit economics. Full...

Signal API · MCP

Track Tempus AI with the Signal API

One POST /v1/companies/enrich call with tempus.com returns Tempus AI 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"tempus.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Tempus AI 10-Q

When did Tempus AI file its latest 10-Q?
Tempus AI filed its latest 10-Q (Quarter ended Sep 30, 2026) on Nov 2, 2026. The one before it was filed on Jul 30, 2026.
What did Tempus AI disclose in its latest 10-Q?
From the filing dated Nov 2, 2026: Tempus Collaborates with AstraZeneca and Pathos to Build Foundation Multimodal Oncology AI Model
What did Tempus AI say on its recent earnings calls?
Q3 FY2026: Entering $193M five-year data licensing deals with BMS and Pathos (dated Nov 2, 2026).
Where can I read Tempus AI's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1717115/000119312526442624/tem-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →